Dolutegravir
Indication :
- It is an integrase inhibitor used in the treatment of HIV.
Dosing :
<30 kg:
Safety not established.
30 kg-40 kg:
35 mg orally once a day.
>40 kg:
50 mg orally once a day.
Adverse Effect :
Hypercholesterolemia, hypertriglyceridemia and elevated liver transaminases, lipase, bilirubin, creatine kinase, blood sugar. Can cause arthralgia, myalgia.
Interaction :
Efavirenz, Fosamprenavir/Ritonavir, Tipranavir/Ritonavir, Rifampin: Give twice a day when using along with efavirenz, fosamprenavir/ritonavir, tipranavir/ritonavir, rifampin.
Hepatic Dose :
Mild to moderate hepatic impairment: No dose adjustment required.
Severe hepatic impairment: Use is contraindicated.